Javascript must be enabled to continue!
e0645 Protective effects of simvastatin combined with anisodamine on myocardial perfusion in swine no reflow model
View through CrossRef
Objectives
To evaluated the preventive effect of simvastatin combined with anisodamine on myocardial perfusion in no reflow, and to probe the possible mechanism.
Method
Totally 16 minipig of 30–40 Kg were randomly divided into anisodamine groups (A, n=8) and anisodamine plus simvastatin group (A+S, n=8). Pigs in Group A+S were pretreated with oral simvastatin for 7 days, while pigs in A groups were given placebo. Seven days later, CAG was performed, and the dopper wire was used to record blood velocity. The pressure of aorta (Pa) was monitored. PMBS was injected to establish no reflow model. Anisodamine was injected into the LAD 2 min before PBMS was injected. The TIMI blood flow, TMPG and CTFC were recorded to evaluate the myocardial perfusion. The sample of myocardium in ischaemic zone and normal zone were measured. Blood sample was taken before and after the expeiment to measure the level of CK-MB, cTnI and hs-CRP. The percent of necrostic myocardium was calculated by myocardium stain method.
Results
The TIMI blood flow and TFCs were better in Group A+S (p<0.05). The Pa was increased in both groups after PMBS injection at the early stage (p<0.01), and then it begun to decrease in Group A (p<0.05), while it remained its high level in Group A+S (p=0.042). The bAPV was increased in both groups, which was more obvious in the Group A after PMBS injection. After the injection of PMBS, the hAPV was sinificantly decreased in both groups (p<0.01), but it was still higher in group A+S (p=0.000). The CFR was continously deceased after the PMBS injection (p<0.05), but it was higher in Group A+S (p=0.025). The h-MR was further increased (p=0.024), with no difference between two groups after the PMBS injection. The level of serum cholesterol was similar between the two groups (p=0.063). CK-MB, TnI, hs-CRP and MDA were increased after the experiment, with the higher levels in Group A. NO was also increased (p=0.000), with the higher level in Group A+S (p=0.006). SOD was decreased (p=0.000) in both groups, with lower level in Group A (p=0.000). The infarcted size in group A was larger than that in A+S group (p<0.05).
Conclusion
Simvastatin combined with anisodamine can significantly improve myocardial blood perfusion and porotect the myocardium against ischaemic injury during PCI. The possible mechanism involves improving of coronary haemodynamics, antiinflammation and antioxidation.
Title: e0645 Protective effects of simvastatin combined with anisodamine on myocardial perfusion in swine no reflow model
Description:
Objectives
To evaluated the preventive effect of simvastatin combined with anisodamine on myocardial perfusion in no reflow, and to probe the possible mechanism.
Method
Totally 16 minipig of 30–40 Kg were randomly divided into anisodamine groups (A, n=8) and anisodamine plus simvastatin group (A+S, n=8).
Pigs in Group A+S were pretreated with oral simvastatin for 7 days, while pigs in A groups were given placebo.
Seven days later, CAG was performed, and the dopper wire was used to record blood velocity.
The pressure of aorta (Pa) was monitored.
PMBS was injected to establish no reflow model.
Anisodamine was injected into the LAD 2 min before PBMS was injected.
The TIMI blood flow, TMPG and CTFC were recorded to evaluate the myocardial perfusion.
The sample of myocardium in ischaemic zone and normal zone were measured.
Blood sample was taken before and after the expeiment to measure the level of CK-MB, cTnI and hs-CRP.
The percent of necrostic myocardium was calculated by myocardium stain method.
Results
The TIMI blood flow and TFCs were better in Group A+S (p<0.
05).
The Pa was increased in both groups after PMBS injection at the early stage (p<0.
01), and then it begun to decrease in Group A (p<0.
05), while it remained its high level in Group A+S (p=0.
042).
The bAPV was increased in both groups, which was more obvious in the Group A after PMBS injection.
After the injection of PMBS, the hAPV was sinificantly decreased in both groups (p<0.
01), but it was still higher in group A+S (p=0.
000).
The CFR was continously deceased after the PMBS injection (p<0.
05), but it was higher in Group A+S (p=0.
025).
The h-MR was further increased (p=0.
024), with no difference between two groups after the PMBS injection.
The level of serum cholesterol was similar between the two groups (p=0.
063).
CK-MB, TnI, hs-CRP and MDA were increased after the experiment, with the higher levels in Group A.
NO was also increased (p=0.
000), with the higher level in Group A+S (p=0.
006).
SOD was decreased (p=0.
000) in both groups, with lower level in Group A (p=0.
000).
The infarcted size in group A was larger than that in A+S group (p<0.
05).
Conclusion
Simvastatin combined with anisodamine can significantly improve myocardial blood perfusion and porotect the myocardium against ischaemic injury during PCI.
The possible mechanism involves improving of coronary haemodynamics, antiinflammation and antioxidation.
Related Results
e0043 Effects of simvastatin on angiogenesis and the expression of Ang1 after myocardial infarction in rats
e0043 Effects of simvastatin on angiogenesis and the expression of Ang1 after myocardial infarction in rats
Objective
To investigate the effects of simvastatin on myocardial angiogenesis and the expression of angiopoietin-1 after experimental myocardial infarction (MI) ...
MYOCARDIAL PROTECTIVE EFFECTS OF ANISODAMINE IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING EARLY PERCUTANEOUS CORONARY INTERVENTION FOLLOWING THROMBOLYSIS
MYOCARDIAL PROTECTIVE EFFECTS OF ANISODAMINE IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING EARLY PERCUTANEOUS CORONARY INTERVENTION FOLLOWING THROMBOLYSIS
Objectives
To evaluate the additional benefit of preventive administration of anisodamine to tirofiban during primary PCI on myocardial reperfusion.
...
e0044 The role of Ang1 and eNOS in the proangiogenic effect of simvastatin after myocardial infarction in rats
e0044 The role of Ang1 and eNOS in the proangiogenic effect of simvastatin after myocardial infarction in rats
Objective
To investigate the roles of angiopoietin-1 (Ang-1) and endothelial nitric oxide synthase (eNOS) in pro-angiogenic effect of simvastatin after experiment...
GW24-e3967 Effects of simvastatin on vascular endothelial function in patients with coronary heart diseases
GW24-e3967 Effects of simvastatin on vascular endothelial function in patients with coronary heart diseases
Objectives
To investigate the effects of simvastatin therapy on vascular endothelial function in patients with coronary heart diseases (CAD).
...
Simvastatin dengan Senyawa Turunan Β-Siklodextrin
Simvastatin dengan Senyawa Turunan Β-Siklodextrin
This study aims to determine the profile of the inclusion complex formed between simvastatin and β-cyclodextrin and its derivatives. To determine the level of stability and determi...
Knowledge and practices related to swine flu in school students of Bhavnagar, Gujarat
Knowledge and practices related to swine flu in school students of Bhavnagar, Gujarat
Context: Swine Flu caused by Influenza virus of H1N1 strain is a highly infectious respiratory disease. Knowledge and awareness among the community regarding the containment of spr...
Mortality predictors in patients with ST-segment elevation myocardial infarction presenting no-reflow phenomenon after primary PCI: experience of a tertiary center
Mortality predictors in patients with ST-segment elevation myocardial infarction presenting no-reflow phenomenon after primary PCI: experience of a tertiary center
Abstract
The mortality rate in subjects with ST-segment elevation acute myocardial infarction (STEMI) is increased because of short- and long-term complications.
...
Simvastatin suppressed HMGB1-RAGE axis and atherosclerosis via mevalonate pathway
Simvastatin suppressed HMGB1-RAGE axis and atherosclerosis via mevalonate pathway
Objective
Recent studies suggested that high mobility group box 1 (HMGB1) and receptor for advanced glycation end products (RAGE) contribute to atherosclerosis, a...

